Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Trial to Study Single and Multiple Ascending Doses of Oral BCX9930 in Healthy Subjects

Next Previous
Trial Profile

A Phase I Trial to Study Single and Multiple Ascending Doses of Oral BCX9930 in Healthy Subjects

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 22 Dec 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pelecopan (Primary)
  • Indications Paroxysmal nocturnal haemoglobinuria
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Sponsors BioCryst Pharmaceuticals

Most Recent Events

  • 15 Dec 2022 According to a BioCryst Pharmaceuticals media release, based on new competitive data recently presented at the American Society of Hematology (ASH) annual meeting, the company no longer believes that BCX9930 would be commercially competitive, and is discontinuing the development of BCX9930. This decision allows the company to fully focus its complement inhibitor development efforts on BCX10013
  • 15 Dec 2022 Status changed from recruiting to discontinued as per BioCryst Pharmaceuticals media release
  • 12 Jan 2020 According to a BioCryst Pharmaceuticals media release, the company has completed an additional MAD cohort with 50 mg of oral BCX9930 or placebo administered every 12 hours for 14 days, with vaccination instead of an antibiotic.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top